166 related articles for article (PubMed ID: 18954713)
1. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
Seshadri M; Bellnier DA; Cheney RT
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1198-207. PubMed ID: 18954713
[TBL] [Abstract][Full Text] [Related]
2. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
3. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
4. Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.
Seshadri M; Mazurchuk R; Spernyak JA; Bhattacharya A; Rustum YM; Bellnier DA
Neoplasia; 2006 Jul; 8(7):534-42. PubMed ID: 16867215
[TBL] [Abstract][Full Text] [Related]
5. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
6. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
Seshadri M; Ciesielski MJ
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1373-82. PubMed ID: 19458603
[TBL] [Abstract][Full Text] [Related]
7. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors.
Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT
Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671
[TBL] [Abstract][Full Text] [Related]
8. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
[TBL] [Abstract][Full Text] [Related]
9. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
Seshadri M; Spernyak JA; Maiery PG; Cheney RT; Mazurchuk R; Bellnier DA
Neoplasia; 2007 Feb; 9(2):128-35. PubMed ID: 17356709
[TBL] [Abstract][Full Text] [Related]
10. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
Seshadri M; Sacadura NT; Coulthard T
Angiogenesis; 2011 Dec; 14(4):491-501. PubMed ID: 21901534
[TBL] [Abstract][Full Text] [Related]
11. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
[TBL] [Abstract][Full Text] [Related]
12. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
[TBL] [Abstract][Full Text] [Related]
13. Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Galbraith SM; Rustin GJ; Lodge MA; Taylor NJ; Stirling JJ; Jameson M; Thompson P; Hough D; Gumbrell L; Padhani AR
J Clin Oncol; 2002 Sep; 20(18):3826-40. PubMed ID: 12228202
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): Increased tumor vascular permeability.
Zhao L; Ching LM; Kestell P; Kelland LR; Baguley BC
Int J Cancer; 2005 Aug; 116(2):322-6. PubMed ID: 15800918
[TBL] [Abstract][Full Text] [Related]
15. Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model.
Howe FA; McPhail LD; Griffiths JR; McIntyre DJ; Robinson SP
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1470-6. PubMed ID: 18538948
[TBL] [Abstract][Full Text] [Related]
16. Acute vascular disruption by 5,6-dimethylxanthenone-4-acetic Acid in an orthotopic model of human head and neck cancer.
Seshadri M; Toth K
Transl Oncol; 2009 Aug; 2(3):121-7. PubMed ID: 19701496
[TBL] [Abstract][Full Text] [Related]
17. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model.
Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V
Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497
[TBL] [Abstract][Full Text] [Related]
18. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
[TBL] [Abstract][Full Text] [Related]
19. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Joseph WR; Cao Z; Mountjoy KG; Marshall ES; Baguley BC; Ching LM
Cancer Res; 1999 Feb; 59(3):633-8. PubMed ID: 9973211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
